Nexalin Technology (NASDAQ:NXL – Get Free Report) and Enovis (NYSE:ENOV – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.
Profitability
This table compares Nexalin Technology and Enovis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
| Enovis | -47.96% | 12.03% | 4.91% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Nexalin Technology and Enovis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
| Enovis | 1 | 1 | 10 | 0 | 2.75 |
Valuation and Earnings
This table compares Nexalin Technology and Enovis”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexalin Technology | $300,000.00 | 8.83 | -$8.22 million | ($14.41) | -0.25 |
| Enovis | $2.25 billion | 0.45 | -$1.18 billion | ($19.26) | -0.92 |
Nexalin Technology has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Nexalin Technology has a beta of 4.08, suggesting that its share price is 308% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Insider & Institutional Ownership
0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by insiders. Comparatively, 2.9% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Enovis beats Nexalin Technology on 8 of the 14 factors compared between the two stocks.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
